EuroBiotech: More Articles of Note

> PharmaMar (BME:PHM) began a pivotal single-arm trial of a treatment for relapsed and refractory angioimmunoblastic T-cell lymphoma. The 60-person study will assess the efficacy of plitidepsin in terms of overall response rate. "After the recent announcement of the positive results obtained with plitidepsin in patients with multiple myeloma, we are continuing with the development of this molecule in other hematological tumors such as angioimmunoblastic T-cell lymphoma," PharmaMar’s Arturo Soto said in a statement. Release

> Galapagos ($GLPG) posted an update on its pipeline progress at a meeting in New York, NY to discuss its R&D strategy. The Belgian biotech used the session to post Phase I data on one of its AbbVie ($ABBV)-partnered cystic fibrosis drugs and a Servier-partnered osteoarthritis asset. Both trials suggested the drugs are well tolerated. Galapagos also detailed plans to bolster its early-phase pipeline by moving treatments for idiopathic pulmonary fibrosis and atopic dermatitis into the clinic next year. Release

> Aprea named Christian Schade as its CEO. The move gives the Swedish cancer biotech a Boston, MA-based CEO with a track record of leading drug developers to trade sales. Schade last worked as CEO of Novira Therapeutics, a hepatitis B player that was bought by Johnson & Johnson ($JNJ) late in 2015. Earlier in his career, Schade worked as CFO of Omthera and Medarex at the time of their takeovers by AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMS), respectively. Aprea’s lead asset is designed to reactivate mutant p53 protein. Release

> 4D pharma (LON:DDDD) received clearance from regulators to restart a Phase I trial of its live biotherapeutic Thetanix. Quality concerns at a third-party supplier of the treatment for pediatric Crohn's disease had prompted 4D to stop dosing patients in the study. Now, having wrapped up an investigation into the matter and gained the green light from regulators, 4D has resumed the trial. Statement

> ReNeuron (LON:RENE) wrapped up enrollment in its Phase II stroke disability clinical trial. The milestone sets ReNeuron up to deliver three-month follow-up data on its cell therapy before the end of the year. In parallel to the advance of the trial, ReNeuron is talking to regulators on both sides of the Atlantic about the design of a Phase II/III study. If the Phase II data meet expectations, ReNeuron plans to file to run the larger study in the first quarter of next year. Release

> Wilex (FRA:WL6) subsidiary Heidelberg Pharma teamed up with Advanced Proteome Therapeutics (APC) to work on cancer drugs. The collaboration pairs Heidelberg’s antibody-drug conjugate (ADC) technology with protein-modification tools developed by APC. "The application of our site-specific technology to Heidelberg Pharma's novel payload has the potential to result in examples of more homogeneous and more effective ADCs,” APC CEO Allen Krantz said in a statement. Release